Athira Pharma (ATHA)
(Real Time Quote from BATS)
$3.26 USD
-0.04 (-1.21%)
Updated Jul 25, 2024 11:16 AM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ATHA 3.26 -0.04(-1.21%)
Will ATHA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ATHA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ATHA
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
ATHA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
All You Need to Know About Athira Pharma, Inc. (ATHA) Rating Upgrade to Buy
Other News for ATHA
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
Director Kelly Romano Acquires 42,400 Shares of Athira Pharma Inc (ATHA)
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), Gilead Sciences (GILD) and Inspire Medical Systems (INSP)
Analysts Offer Insights on Healthcare Companies: Athira Pharma (ATHA), AbbVie (ABBV) and LENSAR (LNSR)
Analysts Are Bullish on These Healthcare Stocks: Taysha Gene Therapies (TSHA), Athira Pharma (ATHA)